Cancer – BrainChild-04: Phase 1 Study Of B7-H3, EGFR806, HER2, AND IL13-zetakine (QUAD) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

What is the goal of this study?

Seattle Children's is testing a CAR T-cell therapy, called SC-CAR4BRAIN, in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG).

Through this phase 1 trial, researchers are working to answer these questions:

• Is SC-CAR4BRAIN safe to give to children and young adults with DIPG, DMG or relapsed or refractory CNS tumors?
• What is the best dose of SC-CAR4BRAIN for children and young adults with DIPG, DMG or relapsed or refractory CNS tumors?
• How does SC-CAR4BRAIN work against CNS tumors?

Learn how T-cell therapy works.

Who can join the study?

This study might be a good fit for children and young adults who:

• Are ages 1 to 26 years old
• Have DIPG, DMG or a refractory or recurrent CNS tumor.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

In this trial, a patient’s own T cells are reprogrammed to recognize and target the proteins B7-H3, EGFR806, HER2, AND IL13-zetakine which are present on the surface of many pediatric brain tumors. The reprogrammed cells will be put back into the patient’s body through a catheter.

Read more about the BrainChild-04 study on clinicaltrials.gov.

Who can I contact for more information?

For more information, please call 206-987-2106 or send us an email.